Outlook Therapeutics Inc (OTLK)
7.78
+0.45
(+6.14%)
USD |
NASDAQ |
May 17, 16:00
7.78
0.00 (0.00%)
After-Hours: 20:00
Outlook Therapeutics Enterprise Value: 179.61M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 179.61M |
| May 16, 2024 | 169.08M |
| May 15, 2024 | 171.42M |
| May 14, 2024 | 170.72M |
| May 13, 2024 | 173.99M |
| May 10, 2024 | 174.12M |
| May 09, 2024 | 177.61M |
| May 08, 2024 | 183.90M |
| May 07, 2024 | 188.80M |
| May 06, 2024 | 195.55M |
| May 03, 2024 | 197.88M |
| May 02, 2024 | 195.55M |
| May 01, 2024 | 195.55M |
| April 30, 2024 | 205.34M |
| April 29, 2024 | 209.53M |
| April 26, 2024 | 193.92M |
| April 25, 2024 | 188.33M |
| April 24, 2024 | 188.56M |
| April 23, 2024 | 188.56M |
| April 22, 2024 | 186.00M |
| April 19, 2024 | 187.86M |
| April 18, 2024 | 190.66M |
| April 17, 2024 | 198.12M |
| April 16, 2024 | 201.38M |
| April 15, 2024 | 198.35M |
| Date | Value |
|---|---|
| April 12, 2024 | 189.03M |
| April 11, 2024 | 196.51M |
| April 10, 2024 | 195.41M |
| April 09, 2024 | 201.35M |
| April 08, 2024 | 203.34M |
| April 05, 2024 | 201.35M |
| April 04, 2024 | 207.08M |
| April 03, 2024 | 198.27M |
| April 02, 2024 | 211.04M |
| April 01, 2024 | 223.37M |
| March 28, 2024 | 283.90M |
| March 27, 2024 | 228.43M |
| March 26, 2024 | 213.54M |
| March 25, 2024 | 209.87M |
| March 22, 2024 | 212.46M |
| March 21, 2024 | 178.14M |
| March 20, 2024 | 172.53M |
| March 19, 2024 | 186.02M |
| March 18, 2024 | 194.22M |
| March 15, 2024 | 133.41M |
| March 14, 2024 | 100.75M |
| March 13, 2024 | 110.28M |
| March 12, 2024 | 117.17M |
| March 11, 2024 | 127.92M |
| March 08, 2024 | 129.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
28.89M
Minimum
Dec 30 2019
564.16M
Maximum
Feb 08 2021
215.40M
Average
206.60M
Median
Enterprise Value Benchmarks
| Cutera Inc | 358.38M |
| Actinium Pharmaceuticals Inc | 207.82M |
| GT Biopharma Inc | -9.664M |
| Karyopharm Therapeutics Inc | 157.92M |
| Marinus Pharmaceuticals Inc | 33.28M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -114.29M |
| Total Expenses (Quarterly) | 18.94M |
| EPS Diluted (Quarterly) | -8.01 |
| Earnings Yield | -146.7% |
| Normalized Earnings Yield | -544.19 |